Latest News - Headache & Pain

Friday, January 18, 2019

Wireless Spinal Cord Stimulator Provides Relief from Chronic Pain

Clinical trial results showed that the world’s first wireless, fully programmable neuromodulation system (Freedom SCS System; Stimwave Technologies, Pompano Beach, FL) provided significant relie…

Read the full story

Wednesday, January 16, 2019

Registry for Peripheral Nerve Stimulation for Pain Management Is Launched

The first registry related to peripheral nerve stimulation (PNS) for pain management is enrolling patients. The registry will collect long-term clinical data with the goal of educating physicians on h…

Read the full story

Tuesday, January 08, 2019

Federal Supply Schedule Adds External Vagus Nerve Stimulator for Headache Prevention and Treatment

A noninvasive vagus nerve stimulation (nVNS) device (gammaCore; electroCore, Basking Ridge, NJU) has been award a 5-year Federal Supply Schedule medical equipment and supply contract that makes the de…

Read the full story

Tuesday, January 08, 2019

Phase 3 Trial of Dioscorea japonica Extracts To Be Initiated for Treatment of Pain From Diabetic Neuropathy

The planned initiation of a phase 3 double-blind, placebo controlled, 12-week study of Dioscorea japonica extracts (NB-01; Neurobo, Boston, MA) for pain relief in patients with diabetic neur…

Read the full story

Thursday, January 03, 2019

American Academy of Neurology Call for Uniformity in Brain Death Standards

Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) is calling for action on t…

Read the full story

Wednesday, January 02, 2019

New Drug Application Accepted for Combined Bupivacaine/Meloxicam for Post-Operative Pain

The Food and Drug Administration (FDA) has accepted a new drug application (NDA) for fixed-dose combined bupivacaine/meloxicam (HTX-011; Heron Therapeutics, San Diego, CA), an investigational, extende…

Read the full story

Friday, December 21, 2018

American Headache Society Releases Statement on Integrating New Treatments for Migraine Into Practice

To provide health care professionals with updated guidance on the use of novel preventive and acute treatments for migraine in adults, the American Headache Society (AHS) published a position statemen…

Read the full story

Thursday, December 13, 2018

Long-Term Safety and Tolerability of Rimegepant for Treatment of Migraine

Initial results from an ongoing, open-label safety study of the oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, show that the drug may be effective and safe for acute trea…

Read the full story

Wednesday, December 05, 2018

Positive Results in Phase 3 Trial of Rimegepant for Oral Acute Treatment of Migraine

Results from a phase 3 clinical trial show that treatment with rimegepant (Zydis; Biohaven, New Haven, CT) provided significantly more relief from pain and most bothersome symptoms (MBS) compared with…

Read the full story

Tuesday, December 04, 2018

Dystonia and Spasticity Patients May Become Immune to Toxin Treatment

People with dystonia or spasticity can get relief from botulinum toxin type A, but a new study published online in Neurology shows that 15% of people treated with the toxin can develop an im…

Read the full story

Wednesday, November 28, 2018

Biases in Dementia Screening Tools

Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice shows that 3 of the most comm…

Read the full story

Tuesday, November 20, 2018

First Patient Enrolled in Study of Oral CGRP Receptor Antagonist for Migraine

The first patient is enrolled in a phase 3 trial for the oral calcitonin gene-related peptide (CGRP) receptor antagonist rimegepant (Biohaven; New Haven, CT). The trial will assess the efficacy and sa…

Read the full story

Monday, November 19, 2018

New Drug Application for Migraine Headache Therapy Lasmitidan

A New Drug Application (NDA) for lasmiditan (Eli Lilly and Company, Indianapolis, IN) has been submitted to the Food and Drug Administration (FDA). Lasmitidan is an investigational, first-in-class the…

Read the full story

Thursday, November 15, 2018

Migraines that Affect Vision May Increase Risk of Atrial Fibrillation

People who experience migraine with visual aura may have an increased risk of atrial fibrillation (AFib), according to a study published in Neurology.  Participants in thelongitudinal, co…

Read the full story

Wednesday, November 14, 2018

Study Confirms Benefits of Laser Interstitial Thermal Therapy

A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed positive outcomes for lase…

Read the full story
Load More